A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

PURPOSE: A Phase I dose-escalation study was performed to determine the maximum tolerated dose (MTD) of the immunotoxin VB4-845 in patients with nonmuscle-invasive bladder cancer (NMIBC) refractory to or intolerant of bacillus Calmette–Guerin (BCG). Secondary objectives included evaluation of the sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowalski, Mark, Entwistle, Joycelyn, Cizeau, Jeannick, Niforos, Demi, Loewen, Shauna, Chapman, Wendy, MacDonald, Glen C
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998804/
https://www.ncbi.nlm.nih.gov/pubmed/21151619
http://dx.doi.org/10.2147/DDDT.S14071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998804/
https://www.ncbi.nlm.nih.gov/pubmed/21151619
http://dx.doi.org/10.2147/DDDT.S14071

Ejemplares similares